ArticleBJUI compass2025
Real-world oncological and toxicity outcomes with the Moscow strain of intravesical BCG for non-muscle invasive bladder cancer-Implications for global shortage.
Article in BJUI compass, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Diagnosis, evaluation, and management of patients with non-muscle invasive bladder cancer.Future science OA · 2026Review
- Improving photodynamic therapy efficacy in bladder cancer using polymer micelle-encapsulated pheophorbide a.Translational oncology · 2026Article
- Real-world oncological and toxicity outcomes with the Moscow strain of intravesical BCG for non-muscle invasive bladder cancer-Implications for global shortage.BJUI compass · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to determine the oncological effectiveness and adverse-effect profile of the Moscow strain of intravesical bacille Calmette-Guérin (BCG) for intermediate and high-risk non-muscle invasive bladder cancer (NMIBC). Materials and methods: We performed a retrospective search of consecutive intermediate and high-risk non-muscle invasive bladder cancer patients who were started on intravesical BCG at 80 mg dose from January 2020 to December 2021. Data were collected for oncological outcomes and adverse effects of BCG. High-grade recurrence-free survival (HGRFS) was defined as any relapse of high-grade (HG) urothelial cancer or carcinoma in situ (CIS). The primary outcome was to determine the HGRFS for those with originally HG disease. The RFS and HGRFS were calculated for the entire cohort, and also stratified by whether the patients had received adequate BCG or not. Results: We identified 166 patients during the study period, of which 79.6% had HG disease. There were 25 recurrences (15.1%) in the entire cohort over a median follow-up of 29 months. The RFS for the entire cohort at 12 and 24 months was 89.8% and 86.7%, respectively. For those with baseline HG disease, the 12- and 24-month HG-RFS was 90.9% and 87.1%. For the overall cohort, those who had received adequate BCG ( Conclusion: The Moscow strain BCG at 80 mg dose has excellent oncological outcomes, especially in patients who can take adequate BCG instillations, but BCG intolerance is a problem in a significant proportion of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.